Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3996
Name urinary system cancer
Definition An organ system cancer that is located_in the kidneys, ureteres, bladder or urethra.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 S249C AZD4547 urinary system cancer sensitive detail...
FGFR3 amp AZD4547 urinary system cancer sensitive detail...
FGFR3 amp Infigratinib urinary system cancer sensitive detail...
FGFR3 S249C Infigratinib urinary system cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01182168 Phase I Cisplatin + Everolimus + Gemcitabine Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Completed USA 0
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated USA 0
NCT02192541 Phase I Aflibercept + Ganetespib Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated USA 0
NCT02365597 Phase II Erdafitinib An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer Active, not recruiting USA | GBR | FRA | ESP | DEU | BEL | AUT 8
NCT02675829 Phase II Ado-trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Recruiting USA 0
NCT02928406 Phase III Atezolizumab A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract Completed NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 23
NCT03084471 Phase III Durvalumab + Tremelimumab Durvalumab An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG) Completed USA | NLD | ITA | GBR | FRA | DEU | CAN 1
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Active, not recruiting USA 0
NCT03375307 Phase II Olaparib Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes Recruiting USA 0
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Recruiting USA 0
NCT04235777 Phase I Bintrafusp alfa + NHS-IL12 TGF-beta Trap (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies Recruiting USA 0
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT06161532 Phase II Atezolizumab + Sacituzumab govitecan-hziy Sacituzumab govitecan-hziy Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer Not yet recruiting USA 0
NCT06253520 Phase I Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Recruiting USA 0
NCT06389123 Phase I 177Lu-DOTA-ABM-5G Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas Recruiting USA 0